PERIODICUM BIOLOGORUM VOL. 117, No 1, 73–79, 2015
UDC 57:61 CODEN PDBIAD ISSN 0031-5362
Effect of Statin Therapy Duration on Bone Turnover Markers in Dyslipidemic Patients OLGA CVIJANOVIĆ1 NENAD BIĆANIĆ2 ŽELJKA CRNČEVIĆ ORLIĆ2 SANJA KLOBUČAR MAJANOVIĆ2 TAMARA TURK WENSVEEN2 IVAN BUBIĆ3 Department of Anatomy, Medical Faculty of Rijeka, University of Rijeka, Croatia
1
Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
2
Department of Nephrology, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
3
Correspondence: Olga Cvijanovi} ,MD, PhD Department of Anatomy Medical Faculty of Rijeka, University of Rijeka Bra}e Branchetta 20, 51000 Rijeka Email:
[email protected]
Abstract Background and Purpose: Statins are cholesterol-lowering drugs decreasing bone resorption by inhibition of the farnesyl diphosphate synthase step in the mevalonic acid pathway and therefore are believed to have beneficial effects on bone status. The objective was to examine the relationship between statin therapy duration and bone turnover markers in dyslipidemic patients. Patients and Methods: Two hundred and eighty subjects were divided into five groups depending on duration of statin therapy: (controls 0 yrs); (0.11.5 yrs); (2-5 yrs); (6-10 yrs); (11-30 yrs). ELISA method was applied on fasting serums using bone formation markers: Osteoprotegerin (pmol/l) and Osteocalcin (ng/ml) and bone resorption markers: sRANKL (pmol/l) and CrossLaps (ng/ml). In statistical analysis, multiple regressions were used. Results: A common influence of studied predictor variables was statistically significant for sRANKL, Serum CrossLaps and osteocalcin (P
